A complaint filed by Amgen in the U.S. District Court for the District of New Jersey in March tells a different story. In that proceeding, Amgen seeks relief from Sandoz's alleged violations of the biosimilar patent dance provisions of the BPCIA. Specifically, Amgen asserts that Sandoz's attempts to cut the dance short by agreeing with Amgen's list of patents, "waiving" its right to receive Amgen's responsive statement under 42 U.S.C. § 262( l )(3)(C), and declaration that "negotiations pursuant to 42 U.S.C. § 262( l )(4) and (5) were unnecessary" violated the BPCIA. (Similar issues have been raised in the biosimilar litigation between Janssen Biotech, Inc. and Celltrion Healthcare Co., Ltd. over Remicade®.) The New Jersey case is still pending, but it appears that the parties may have engaged in further negotiations between March and April that led to the filing of the biosimilar patent litigation in California.